Publication / Source: Bioanalysis 5(12)
Authors: Wright L, Baughman S, Wake A
“…the challenges that remain associated with supporting drug development, characterization, preclinical and clinical studies are extensive and, notably, require a different set of expertise than typical biologic programs.”
Combining the specificity of a monoclonal antibody (mAb) with the potency of a cytotoxic anticancer product produces a therapeutic agent capable of a highly specific delivery of a drug to the target of concern. Furthermore, this is achieved without inducing any detriment to surrounding tissue and, thus, has the potential for fewer toxic side effects and an increased therapeutic window.